Literature DB >> 8863660

Detection of Epstein-Barr virus-infected mucosal lymphocytes in nasal polyps.

Q Tao1, G Srivastava, P Dickens, F C Ho.   

Abstract

Primary nasal lymphomas of T or NK cell origin are known to be associated with Epstein-Barr virus (EBV). However, it is not known whether EBV is normally present in nasal mucosa as distinct to nasopharyngeal tissue. This study investigates the prevalence of EBV infection in 13 cases of nasal polyps. EBV DNA was detected in 2 of 13 (15%) by Southern blot hybridization and in 9 of 13 (69%) by polymerase chain reaction. In situ hybridization for EBV-encoded small nuclear RNAs (EBER) was positive in 11 of 13 (85%) cases; the virus was present in stromal lymphocytes only and not in the epithelial cells. Immunohistochemistry for EBV proteins in 7 cases revealed EBV nuclear antigen (EBNA)-2, latent membrane protein (LMP)-1, and ZEBRA (the switch protein encoded by gene BZLF1) expression in rare isolated stromal lymphocytes in 3 cases. Double immunostaining in 1 case showed that the LMP-1+ cells were B or T cells. Immunohistochemistry for EBV lytic proteins showed very rare viral capsid antigen (VCA)+ and membrane antigen (MA)+ cells in 1 case and very rare diffuse early antigen (EA-D)+ and VCA+ cells in 1 other case. The expression of ZEBRA, EA-D, VCA, and MA suggested a disruption of latency in very rare stromal lymphocytes leading to a productive cycle. Although the incidence of EBV positivity in nasal polyps in our population is high (85%), very low numbers of EBV+ cells are found in each case. Nevertheless, they indicate that nasal mucosa could be one of the sites of EBV persistence through a low level of infection of the resident lymphocytes and thereby provide a possible setting for the emergence of virally associated tumors in this site.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8863660      PMCID: PMC1865191     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  23 in total

1.  Microbiologic analyses of nasal polyp tissue.

Authors:  S L Dunnette; M M Hall; J A Washington; E B Kern; T J McDonald; G W Facer; G J Gleich
Journal:  J Allergy Clin Immunol       Date:  1986-07       Impact factor: 10.793

2.  Angiocentric lymphoproliferative disorders of the respiratory system: incrimination of Epstein-Barr virus in pathogenesis.

Authors:  S C Peiper
Journal:  Blood       Date:  1993-08-01       Impact factor: 22.113

3.  Improved double immunohistochemical staining method for cryostat and paraffin wax sections, combining alkaline phosphatase anti-alkaline phosphatase and indirect immunofluorescence.

Authors:  Q Tao; G Srivastava; S L Loke; E Y Chan; F C Ho
Journal:  J Clin Pathol       Date:  1994-07       Impact factor: 3.411

4.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

5.  Long internal direct repeat in Epstein-Barr virus DNA.

Authors:  A Cheung; E Kieff
Journal:  J Virol       Date:  1982-10       Impact factor: 5.103

6.  Nasal polyps in asthma and rhinitis. A review of 6,037 patients.

Authors:  G A Settipane; F H Chafee
Journal:  J Allergy Clin Immunol       Date:  1977-01       Impact factor: 10.793

7.  Epstein-Barr virus is localized in the tumour cells of nasal lymphomas of NK, T or B cell type.

Authors:  Q Tao; F C Ho; S L Loke; G Srivastava
Journal:  Int J Cancer       Date:  1995-01-27       Impact factor: 7.396

8.  Replication of Epstein-Barr virus in human epithelial cells infected in vitro.

Authors:  J W Sixbey; E H Vesterinen; J G Nedrud; N Raab-Traub; L A Walton; J S Pagano
Journal:  Nature       Date:  1983 Dec 1-7       Impact factor: 49.962

9.  Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus.

Authors:  I Anagnostopoulos; M Hummel; C Kreschel; H Stein
Journal:  Blood       Date:  1995-02-01       Impact factor: 22.113

10.  Latent sites of Epstein-Barr virus infection.

Authors:  W Y Cheung; A C Chan; S L Loke; G Srivastava; S Pittaluga; L Y Lim; F C Ho
Journal:  Am J Clin Pathol       Date:  1993-11       Impact factor: 2.493

View more
  7 in total

1.  Infection of nonhost species dendritic cells in vitro with an attenuated myxoma virus induces gene expression that predicts its efficacy as a vaccine vector.

Authors:  S Top; E Foulon; B Pignolet; M Deplanche; C Caubet; C Tasca; S Bertagnoli; G Meyer; G Foucras
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  Detection of Epstein-Barr virus-infected lymphoid cells in nasal mucosa or nasopharynx: appearances can be deceptive.

Authors:  Seung Yeon Ha; Jungsuk An; Sanghui Park
Journal:  Virchows Arch       Date:  2013-03-21       Impact factor: 4.064

3.  Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.

Authors:  Ai-Di Gu; Li-Xia Lu; Yan-Bo Xie; Li-Zhen Chen; Qi-Sheng Feng; Tiebang Kang; Wei-Hua Jia; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2009-08-23       Impact factor: 5.531

4.  The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer.

Authors:  Bianfei Shao; Yixiao Feng; Hongbin Zhang; Fang Yu; Qianqian Li; Cui Tan; Hongying Xu; Jianming Ying; Lili Li; Dejuan Yang; Weiyan Peng; Jun Tang; Shuman Li; Guosheng Ren; Qian Tao; Tingxiu Xiang
Journal:  J Cell Mol Med       Date:  2017-11-29       Impact factor: 5.310

5.  Investigation of the role of major respiratory viruses in the aetiology of nasal polyps using polymerase chain reaction technique.

Authors:  F Aksoy; A Yenigun; R Dogan; F Yilmaz; O Ozturan; V B Yenigun
Journal:  J Laryngol Otol       Date:  2014-04-15       Impact factor: 1.469

6.  Comparative Viral Sampling in the Sinonasal Passages; Different Viruses at Different Sites.

Authors:  Rachel K Goggin; Catherine A Bennett; Ahmed Bassiouni; Seweryn Bialasiewicz; Sarah Vreugde; Peter-John Wormald; Alkis J Psaltis
Journal:  Front Cell Infect Microbiol       Date:  2018-09-19       Impact factor: 5.293

7.  Herpes viruses and human papilloma virus in nasal polyposis and controls.

Authors:  Dimitrios Ioannidis; Vasileios A Lachanas; Zoe Florou; John G Bizakis; Efthymia Petinaki; Charalampos E Skoulakis
Journal:  Braz J Otorhinolaryngol       Date:  2015-09-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.